Previous 10 | Next 10 |
Cellular Biomedicine Group (NASDAQ: CBMG ) prices its public offering of 1,029,412 common stock at a price of $17.00/share, for gross proceeds of ~$17.5M. More news on: Cellular Biomedicine Group, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Biogen (NASDAQ: BIIB ) -27% after aducanumab flop. More news on: Biogen Inc., Pyxis Tankers Inc., Staffing 360 Solutions, Inc., Stocks on the move, Read more ...
NEW YORK , March 21, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the pricing of ...
NEW YORK , March 20, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc . (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it ...
SHANGHAI and NEW YORK , Feb. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announc...
Cellular Biomedicine (NASDAQ: CBMG ): FY GAAP EPS of -$2.20 misses by $0.60 . Revenue of $0.22M (-35.3% Y/Y) misses by $0.08M . Press Release More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news,
SHANGHAI and NEW YORK , Feb. 19, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (NASDAQ: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported bus...
Deals and Financings MabPlex, a biologics CDMO located in Yantai, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital, two state-owned investors. Founded in 2013, MabPlex offers biologics development and manufacturing services, including mAbs, recombina...
Deals and Financings Apollomics, a Foster City-Hangzhou innovative oncology biopharma, raised $100 million in a Series B financing, led by CMB International, a subsidiary of China Merchants Bank. Previously, Apollomics was known as CBT, the drug development spin-out of cancer CRO Crown Bio...
Cellular Biomedicine (NASDAQ: CBMG ): Q3 GAAP EPS of -$0.72 misses by $0.21 . More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellular Biomedicine Group Inc. Company Name:
CBMG Stock Symbol:
NASDAQ Market:
Cellular Biomedicine Group Inc. Website:
Cellular Biomedicine Group, Inc. Announces Completion of Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (th...
Cellular Biomedicine Group, Inc. Stockholders Approve Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 8, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting...
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company,...